Abstract
Introduction: Antiphospholipid antibody syndrome (APS) is associated with an increased risk of thrombosis. CTEPH developing from APS is often complicated by multiorgan injury.
Objectives: To identify the predictors of morbility and mortality in patients with APS undergoing pulmonary thromboendarterectomy.
Methodology: A descriptive, retrospective, longitudinal and analytical study was carried out in patients with diagnosis of APS, who underwent endarterectomy from January 2010 to January 2021.
Results: 23 patients were included. 65% women, age of 36 years. 13 patients were triple positive, 4 of whom had secondary APS. 94% of living patients were positive for anti-β2 glycoprotein I (anti-β2GPI) and 90% of all patients were positive for lupus anticoagulant. Mortality represented 21%. The major postoperative complication was thrombocytopenia in 79%. Massive hemorrhage was the cause of death in 4 patients and a negative association was found for hemoptysis and septic shock with anti-β2GPI and anticardiolipin (p=0.012 and p=0.024, respectively). The survival, according to ROC curves, was statistically related to lower preoperative lymphocyte count with a cut-off point of 1720 lymphocytes/mm3, for a likelihood ratio + of 1.3, sensitivity of 77.8% and specificity of 40%.
Conclusions: The autoimmune component related to the lower level of lymphocytes was associated with higher mortality, but this parameter is something seen in patients with CTEPH in other studies. We concluded that it is not a relevant factor that increase the mortality.
Footnotes
Cite this article as Eur Respir J 2022; 60: Suppl. 66, 4193.
This article was presented at the 2022 ERS International Congress, in session “-”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2022